MPOXED

WHO recommends rapid treatment initiation for people living with HIV and mpox

July 16, 2025

In its May 2025 guideline update, the World Health Organization (WHO) strongly recommends rapid initiation of antiretroviral therapy (ART) for individuals living with HIV who are diagnosed with mpox. This aligns with WHO’s broader strategy promoting same-day ART to reduce mortality and achieve viral suppression. People with advanced HIV, particularly those with CD4 counts below 200 cells/mm³, face significantly higher risks of severe mpox outcomes. WHO’s guidance also urges early HIV and syphilis testing in all suspected mpox cases, reinforcing the need for integrated care approaches to improve survival and reduce complications in co-infected patients.

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely

July 16, 2025

With the World Health Organization extending mpox’s public health emergency status in July 2025, NanoViricides, Inc. reaffirmed the importance of its candidate NV-387. Positioned as a broad-spectrum, host-mimetic antiviral, NV-387 is designed to block viral entry by mimicking human cell receptors, potentially limiting viral escape through mutation. Unlike prior antivirals like tecovirimat or brincidofovir, which have shown limited efficacy or adverse effects in mpox patients, NV-387 showed strong safety signals in Phase I trials. NanoViricides plans to launch a Phase II trial in Africa to assess dosing and efficacy. Success could unlock broader pandemic preparedness and bioterrorism market opportunities.

4 new Mpox cases reported in Taiwan, risks high until September: CDC

July 15, 2025

Taiwan’s Centers for Disease Control has confirmed four new mpox cases, including one imported from China, signaling elevated transmission risk through September. All cases involved unvaccinated men in their 30s who developed classic symptoms such as rashes and pustules. Authorities warn that increased summer travel and social gatherings heighten outbreak potential. Since June 2022, Taiwan has reported 473 cases—exclusively of the Clade IIb strain. Vaccination uptake has reached over 99,000 first doses and 68,000 second doses, but continued outreach is vital. The CDC urges at-risk individuals to vaccinate promptly, as two doses reduce severe illness and death by up to 90%.

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387

July 14, 2025

NanoViricides, Inc. is preparing to launch a Phase II adaptive clinical trial of its antiviral candidate NV-387 for Clade Ia and Ib mpox, aiming to evaluate safety, dosing, and efficacy. The trial will begin in the Democratic Republic of the Congo and use a dissolvable oral gummy formulation to ease administration in patients with painful lesions. If successful, NV-387 could become the first human-tested antiviral for orthopoxviruses. This trial arrives as existing options like tecovirimat have underperformed, and Clade I mpox remains a growing global concern. Further support and scrutiny will be crucial as the study advances.

Should the USA Follow France By Offering Mpox Boosters

July 11, 2025

As the World Health Organization maintains mpox as a public health emergency of international concern, debate grows over the need for booster doses of the JYNNEOS vaccine. France has recommended a third dose for high-risk individuals, citing stronger antibody persistence. However, the U.S. Centers for Disease Control and Prevention (CDC) remains cautious, citing low breakthrough rates and mild disease in vaccinated individuals. A recent African preprint study supports long-term immune memory from the two-dose series but notes increased side effects with boosters. As global cases rise, public health agencies must weigh evolving evidence to shape booster strategies grounded in risk.

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

July 10, 2025

Tonix Pharmaceuticals has presented compelling preclinical data on TNX-801, a recombinant horsepox vaccine designed for mpox and smallpox prevention. At the 2025 Vaccine Congress, researchers highlighted TNX-801’s capacity to generate durable immunity from a single subcutaneous dose—offering strong protection without the safety risks associated with traditional vaccinia vaccines. In nonhuman primates, TNX-801 conferred complete protection against Clade I mpox challenge. With promising immunogenicity and attenuation, TNX-801 could be a game-changer in outbreak preparedness. Tonix aims to move into clinical trials soon, positioning this novel candidate as a critical asset in global orthopox virus control strategies.

Mpox cases rise in handful of Africa's outbreak countries

July 10, 2025

As mpox cases decline in Sierra Leone and the Democratic Republic of the Congo, the Africa CDC warns of new surges in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea. With 23 countries reporting outbreaks this year and 18 still active, the epidemic remains highly dynamic. Increases in Uganda and Burundi signal waning public vigilance, while Ghana and Kenya are facing rapid spread and wider community transmission. Vaccine shortages remain a critical barrier to containment beyond Sierra Leone, which has vaccinated over 120,000 people. The continent’s patchwork of responses underscores the urgent need for sustained surveillance, community engagement, and equitable vaccine access.

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country

July 9, 2025

Bavarian Nordic has secured a major contract exceeding DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European nation in 2025, reinforcing efforts to bolster public health security amid rising biological threats. The MVA-BN vaccine, already approved across multiple global markets, serves as a cornerstone for both mpox outbreak response and smallpox preparedness. This order brings Bavarian Nordic’s 2025 public preparedness contracts to over DKK 3 billion. CEO Paul Chaplin emphasized the strategic importance of vaccine readiness in strengthening geopolitical resilience, highlighting continued EU and global partnerships to ensure access to medical countermeasures in a volatile health landscape.

Wayne State part of $3.5 million NIH grant to help develop treatment for mpox

July 9, 2025

A new $3.5 million NIH grant to Wayne State University and UCLA researchers marks a critical step in understanding and combating ocular complications from mpox. As Clade IIb spreads globally, this five-year study will investigate how the virus targets eye tissues, its evolving genetic mutations, and novel antiviral treatments. By combining biosafety level 2 and 3 lab expertise, the project aims to preempt severe eye-related disease outcomes. This collaboration reinforces that pandemic preparedness depends on proactive, cross-institutional research. With the virus rapidly evolving, sustained investment in both scientific inquiry and therapeutic development is imperative for safeguarding public health.

Responding to an mpox outbreak in the heart of Sierra Leone

July 8, 2025

As mpox continues to surge across Sierra Leone, MSF is leading a critical response effort in high-burden districts like Freetown, Bombali, and Kenema. With over 4,000 confirmed cases, stigma, misinformation, and delayed care are fueling preventable suffering, especially for those with painful, advanced disease. MSF’s work—rehabilitating isolation wards, training health workers, supporting psychosocial care, and building diagnostic capacity—is helping restore public trust and improve treatment outcomes. But with every delay, the virus spreads further. The international community must prioritize sustained support for local responders who are battling not only a virus, but also fear, stigma, and resource constraints.

New Multi-Epitope Mpox Vaccine Shows Strong Potential in Silico

July 8, 2025

A new computational vaccine blueprint from University of Dhaka researchers offers promise against monkeypox (mpox), leveraging reverse vaccinology to design a multi-epitope vaccine (MEV) targeting conserved MPXV proteins. In silico modeling revealed strong immune receptor binding and robust T- and B-cell responses, marking a potential leap beyond existing smallpox-based formulations. However, while the immunoinformatics approach is timely amid the Clade Ib resurgence in Africa, no experimental validation has yet been conducted. Further in vitro and in vivo testing is essential before clinical viability can be assessed. This research underscores the power of bioinformatics in pandemic preparedness and next-generation vaccine development.

Management of mpox following removal of HCID status

July 7, 2025

In March 2025, UK public health authorities reclassified all clades of mpox as no longer meeting criteria for high consequence infectious disease (HCID), citing low fatality rates, limited local transmission, and effective vaccine availability. Despite this, public health oversight remains robust. Clinicians are advised to maintain vigilance in diagnosing and managing suspected mpox cases, particularly among vulnerable groups. Updated infection prevention, isolation, and notification protocols remain in place across hospital, community, and home settings. The strategic goal is still elimination of person-to-person transmission, supported by vaccination, clear clinical guidance, and enhanced occupational safety standards for healthcare providers.

Mpox cases decline in Sierra Leone as Africa faces shortage in vaccine funding

July 3, 2025

Sierra Leone's declining mpox cases mark a promising shift in West Africa's outbreak trajectory. The Africa CDC credits this trend to expanded community health worker engagement and effective pairing of vaccination with contact tracing. Yet, a deeper crisis is looming—vaccine stocks are available, but funding has dried up. UNICEF and other procurement partners lack the resources to purchase and distribute doses, even as demand and uptake rise in affected communities. As outbreaks stabilize, the absence of timely investment could undermine hard-won progress. Equity in global health must extend beyond words—resource mobilization is now the critical next step.

WHO donates medical supplies and equipment to boost mpox response

July 3, 2025

WHO has stepped up its support to Sierra Leone’s mpox response with a donation of essential medical supplies, test kits, laboratory equipment, and five medical-grade refrigerators valued at over $126,000. The delivery comes at a pivotal moment as the country battles over 4,000 confirmed mpox cases. The supplies will boost diagnostic and case management capabilities at key treatment sites, including the Hastings Treatment Centre. WHO Country Representative Dr. George Ameh emphasized that the donation reflects a commitment to empowering frontline workers. This contribution not only strengthens the outbreak response but also reinforces long-term health system resilience.

WHO-backed integrated testing model strengthens response to mpox, HIV, and syphilis

July 2, 2025

As mpox cases climb in Central Africa, the Democratic Republic of the Congo (DRC) is setting a precedent with its integrated HIV and syphilis testing program within mpox care. Backed by WHO, the initiative enhances early diagnosis and treatment, especially for high-risk populations. Initial results from Kinshasa show promising uptake and improved case detection. Yet, stock-outs and limited treatment sites highlight the fragility of health infrastructure. The DRC’s approach is a replicable model for resource-limited settings, showing that public health responses to outbreaks can—and must—bridge gaps in broader disease surveillance and care.

Routine vaccination holds key to reducing future mpox outbreaks in England, say researchers

July 2, 2025

New research co-led by the University of Bristol and UK Health Security Agency confirms that routine mpox vaccination programs for gay and bisexual men are both cost-effective and life-saving. The study found that continuous vaccination, with targeted intensification during outbreaks, could cut projected cases in England from 11,000 to 1,000 over a decade while saving the NHS £9 million. As Clade Ib spreads in Sub-Saharan Africa, this model demonstrates the global value of proactive, targeted public health strategies. Ensuring continued access to vaccination is essential to reduce mpox transmission, protect high-risk groups, and preserve public health resources.

Using viral load tests to help predict mpox severity when skin lesions first appear

July 2, 2025

A new study led by Nagoya University offers promising insights into mpox clinical care. Researchers found that measuring viral loads in blood at the onset of skin lesions can predict disease severity in clade I mpox patients. Using data from the Democratic Republic of the Congo, the team identified a threshold—40,000 viral copies per milliliter—beyond which patients are more likely to experience severe, long-lasting symptoms. These findings could help health workers triage patients early and better allocate resources. As the clade I outbreak spreads across Africa, this method may enable faster, more personalized care and improve containment efforts.

UCLA-led team receives $3.5 million NIH grant to develop treatment for mpox: What to know about the viral illness

July 2, 2025

With a new $3.5 million NIH grant, researchers at UCLA and Wayne State University are advancing vital mpox research amid a troubling resurgence in Africa. Their work targets a fast-evolving clade of the virus that disproportionately affects children and poses increasing global risk. By studying viral mutations, eye and skin tissue infection pathways, and testing promising antiviral drug candidates that restore immune function, the team aims to curb transmission and reduce severity. As the U.S. sees sporadic mpox cases, this forward-looking investment is a crucial step toward global preparedness—because ignoring viral threats today could spark tomorrow’s crisis.

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

July 2, 2025

GeoVax’s GEO-MVA vaccine, targeting mpox and smallpox, is gaining momentum as a critical public health asset amid new outbreaks in the U.S., Europe, and Africa. Backed by favorable guidance from the European Medicines Agency (EMA), the vaccine is on an expedited track toward regulatory approval. Its scalable, avian cell-based production platform promises greater manufacturing flexibility and cost-efficiency, addressing the urgent global need for diversified MVA vaccine supply. GeoVax’s pursuit of a BARDA-funded partnership further positions it as a vital complement—or alternative—to current vaccine monopolies. With regulatory and strategic momentum, GEO-MVA may help meet mounting demand in a multipolar outbreak landscape.

New study finds routine vaccination holds key to reducing future mpox outbreaks in England

July 2, 2025

A UK-based study co-led by the University of Bristol and UKHSA finds that routine and surge mpox vaccination strategies among gay and bisexual men are not only life-saving but cost-saving. Modelling suggests such approaches could prevent 10,000 infections and save £9 million over ten years. The research highlights the long-term health and financial benefits of continuous mpox vaccination, especially for at-risk groups. With clade Ib spreading in sub-Saharan Africa and mpox still a global concern, this evidence strongly supports preemptive vaccination policies. Proactive immunization is a prudent investment in public health—not just prevention, but protection and preparedness for future outbreaks.

Taiwan reports highest weekly Mpox cases so far this year

July 1, 2025

Taiwan is witnessing its highest weekly count of locally transmitted mpox cases this year, with four new infections confirmed between June 24 and July 1, all involving men in their 30s. The Taiwan Centers for Disease Control attributes these cases to intimate contact through dating apps, complicating contact tracing. With only 68,193 individuals having completed the two-dose mpox vaccine regimen, public health officials urge full vaccination, especially amid the summer transmission peak. As clade IIb continues to circulate globally, Taiwan’s experience reinforces the need for robust prevention strategies, targeted outreach to at-risk groups, and real-time surveillance to prevent further spread.

Mpox in Sierra Leone: Inside the response to a fast-moving outbreak

July 1, 2025

Sierra Leone is battling its worst mpox outbreak, with over 4,489 infections and 29 deaths since January. While the case fatality rate is low, rapid urban transmission is overwhelming the health system. Médecins Sans Frontières (MSF) has stepped in to support treatment, surveillance, and community outreach, including the establishment of a 50-bed treatment center and infection control efforts. However, stigma, misinformation, and vaccine shortages are undermining containment. As MSF stresses, sustained international assistance is crucial—not only to halt transmission in Sierra Leone but also to prevent further regional spread. This is a test of global solidarity and urgency.

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387

July 1, 2025

NanoViricides’ decision to prioritize mpox as the first indication for its broad-spectrum antiviral candidate NV-387 marks a critical step in epidemic preparedness. With Phase II clinical trials soon to begin in the Democratic Republic of Congo, this novel oral gummy formulation could address urgent treatment gaps, especially in low-resource settings. As other antivirals like tecovirimat fail to show efficacy, NV-387’s promising animal data and host-mimetic nanomedicine approach offer hope. If proven effective, NV-387 could not only fill a void in global mpox treatment but also earn a place in strategic national stockpiles for smallpox and bioterrorism defense.

Health officials encouraged by recent trends in Africa’s mpox outbreaks

June 30, 2025

Mpox trends in Africa show early signs of improvement, with Sierra Leone—once the continent’s largest hotspot—now reporting a relative decline in case share, from 63% to 41% of Africa’s total. Yet with a 91% test positivity rate and over 500 new cases per week, Africa CDC stresses that enhanced surveillance remains critical. Vaccination campaigns have reached nearly 700,000 people across seven countries, but the region still faces a steep shortfall from the 6.4 million doses it needs. As cases rise in Togo and persist in Uganda and the DRC, sustained investment in community health, testing, and vaccines is vital.

AHF Urges Vaccine Equity as Mpox Cases Surge in Sierra Leone

June 30, 2025

As Sierra Leone faces a severe mpox outbreak, accounting for 41% of Africa’s cases, AIDS Healthcare Foundation (AHF) is urging urgent global action. With just 40,000 vaccinated and over 4,300 confirmed cases, the response is overwhelmed. AHF calls on wealthy nations to donate vaccines and demands that Bavarian Nordic lower the cost of its Jynneos vaccine and share production technology with African manufacturers. With 6.4 million doses needed continent-wide, equity must drive the response. Mpox is not just Sierra Leone’s fight—it is a global health emergency that demands affordable tools and collective commitment to end preventable suffering.

Breakthrough Infection, Reinfection Rare but Possible After Mpox Infection or Vaccination

June 28, 2025

New findings from CROI 2025 confirm that mpox reinfection is rare, but not impossible—even among vaccinated individuals. Two studies show that vaccine-induced immunity wanes over time, particularly in people with HIV, and that prior infection does not guarantee lifelong protection. However, the CDC continues to recommend against vaccinating people who have already recovered from mpox, citing the rarity and mild nature of reinfections. These findings underscore the need for ongoing surveillance, research into booster strategies, and nuanced guidance for vulnerable populations, especially as mpox continues to evolve and circulate in both endemic and non-endemic settings.

Hoping that viruses will go away is not enough – what is needed is continuous vigilance

June 26, 2025

Sierra Leone’s growing mpox outbreak is a stark reminder that viruses don’t disappear—they adapt, persist, and resurface where surveillance falters. With over 3,000 confirmed cases and 15 deaths, and clade IIb likely the dominant strain, the country faces mounting strain despite strengthened response efforts. Children remain particularly vulnerable. The outbreak’s rapid spread underscores global risks: infectious threats do not respect borders. Investing in sustained surveillance, equitable vaccine access, and robust local health systems isn’t just ethical—it’s strategic. Sierra Leone’s crisis must catalyze global action before mpox’s resurgence becomes the next international failure of foresight.

Bavarian Nordic begins mpox vaccine trial in pregnant women and infants

June 26, 2025

In a critical move for protecting vulnerable populations, Bavarian Nordic has launched two Phase III trials of its mpox vaccine, Jynneos, in infants under two and pregnant or breastfeeding women in the Democratic Republic of the Congo. Supported by CEPI, EDCTP3, and led by institutions in Kinshasa and Antwerp, the studies will assess vaccine safety and immunogenicity. While this research is vital, funding shortfalls—especially the U.S. withdrawal from GAVI and USAID—threaten equitable access to future doses. The trials may help expand vaccine labels, but global cooperation and sustained financial support are essential to ensure protection reaches those most at risk.

Op-ed: Fighting an mpox outbreak, Sierra Leone ‘shouldn’t have to stand alone’

June 24, 2025

A dangerous mpox outbreak in Sierra Leone is escalating rapidly, with a highly transmissible variant spreading nationwide. Despite impressive local efforts in testing, contact tracing, and genomic surveillance, experts warn that international support is falling short. In a June 11 op-ed in Time, Harvard’s Pardis Sabeti and Christian Happi commend Sierra Leone’s preparedness but emphasize the urgent need for U.S. and global assistance. With disease cases doubling every two weeks and signs of international spread, the moment to act is now. Supporting Sierra Leone’s response is not just aid—it is strategic global health security.

England's Mpox Cases Continues in June 2025

June 24, 2025

England is taking proactive steps to contain rising mpox cases, particularly from the newly emerged clade Ib, with 12 cases confirmed as of May 2025. Most infections are linked to travel from endemic countries, underscoring global interconnectedness in disease spread. In response, England will launch a new routine vaccination campaign in August 2025, combining pre-exposure mpox and gonorrhoea immunizations through sexual health clinics. This integrated approach—backed by WHO concerns over sustained international mpox transmission—marks a critical evolution in STI prevention. England’s timely action could serve as a model for other nations facing imported cases of mpox.

Mpox in Sierra Leone: what’s behind the recent surge and why west Africa is at risk

June 23, 2025

With over 4,000 confirmed mpox cases and 25 deaths as of June 17, 2025, Sierra Leone is facing a rapidly escalating outbreak. Genomic sequencing is underway to trace the virus’s origin, but transmission—primarily among young adults and sex workers—is expanding quickly. As a key regional hub with high mobility, Sierra Leone’s outbreak poses a serious risk to neighboring countries like Liberia and Ghana. Local health authorities are implementing surveillance, contact tracing, and targeted vaccination, but resources remain limited. Without urgent international support, including more testing and vaccines, this could become West Africa’s next regional health crisis.

Sierra Leone’s Mpox Surge Puts Africa’s Epidemic Preparedness to the Test

June 16, 2025

Sierra Leone is confronting a major mpox outbreak, now the third largest in Africa, with over 4,000 confirmed cases. Despite activating a Level 2 emergency response and opening treatment centers, authorities face vaccine shortages and public reluctance toward care. This resurgence underscores regional vulnerability and the urgent need for coordinated leadership from institutions like WAHO and RCSDC. With outbreaks spreading to Togo, Ghana, and Liberia, a region-wide response is essential. Without sufficient vaccine access, funding, and surveillance, containment will falter. Regional solidarity and global investment must rise to meet the moment, turning this crisis into a foundation for lasting preparedness.

LGBTQ+ health centers lead fight against mpox and stigma nationwide

June 13, 2025

The LGBTQ+ community played a pivotal role in stopping the 2022 mpox outbreak in the U.S., not only by embracing safer practices but through the frontline response of community health centers. Clinics like Whitman-Walker and Howard Brown provided affirming, comprehensive care that built trust and encouraged vaccination and early treatment. As mpox reemerges globally, their role remains essential. Yet these centers now face devastating funding threats amid proposals to slash federal support. Safeguarding LGBTQ+ health means sustaining these clinics, investing in tailored care, and confronting stigma—not turning away. Community health centers save lives and should be fortified, not defunded.

Mpox Vaccine Manufacturer Urged to Drop Price Amid Huge Shortfall in Africa

June 13, 2025

Africa is facing a dire mpox vaccine shortfall, with only half of the 6.4 million needed doses funded, warns Africa CDC’s Dr. Ngashi Ngongo. Countries hardest hit—Sierra Leone, Uganda, and the DRC—are struggling as vaccine deliveries fall far short of requests. High prices, especially the $65-per-dose MVA-BN vaccine from Bavarian Nordic, are straining budgets and hindering rollout. UNICEF, also facing a steep income drop, cannot afford the 350,000 remaining doses in its current deal. With U.S. funding sharply cut and testing rates declining in the DRC, urgent global support is needed to avoid a deeper public health crisis.

West Africa: As Mpox cases surge, health workers struggle to keep up

June 12, 2025

The surge in mpox cases in Sierra Leone and Liberia is straining fragile health systems and placing frontline workers at critical risk amid global vaccine shortages. With Sierra Leone reporting over 3,900 infections and Liberia 870 suspected cases, health workers are stretched thin and often unprotected. CARE and national public health agencies are implementing infection control and risk communication, but limited vaccine access threatens containment. This outbreak, driven by a new strain, underscores the urgent need for sustained investment in vaccines and community engagement. Delayed action risks deeper transmission across Africa and beyond—time and resources are running out.

Mpox: updates from the WHO European Region

June 12, 2025

Mpox remains a persistent threat in the WHO European Region, with over 200 cases reported monthly—mostly Clade II infections among men who have sex with men. Although the initial Public Health Emergency of International Concern (PHEIC) was lifted in 2023, the resurgence of Clade Ib in the Democratic Republic of the Congo and its spread in 2024 prompted the WHO to declare a second PHEIC. On 12 June, WHO/Europe will convene Member States to assess surveillance, control, and elimination strategies. This webinar is a timely call to enhance regional preparedness and ensure sustained momentum against a still-active global health threat.

As mpox escalates in Sierra Leone, activity in other countries reflects mixed picture

June 12, 2025

Mpox cases in Africa present a varied landscape—some countries like the DRC and Uganda are seeing declines, while others, including newly affected nations such as Sierra Leone, Liberia, Ghana, and Malawi, face surging infections. Sierra Leone alone accounted for 63% of all confirmed mpox cases in Africa last week. Africa CDC and WHO have extended their respective emergency declarations as vaccine shortages and low testing coverage hamper containment. A shipment of 97,600 vaccine doses is expected mid-June, but challenges with contact tracing and equitable vaccine allocation continue to threaten response effectiveness. Ring vaccination remains critical to stopping further spread.

Sierra Leone Is Battling an Mpox Outbreak. What Happens Next Affects Us All

June 11, 2025

Sierra Leone is at the epicenter of a fast-moving and deadly mpox outbreak. A newly identified variant, G.1, is spreading rapidly, doubling every two weeks, with genomic data suggesting over 11,000 infections. Local teams are responding with remarkable speed—sequencing, tracing, and deploying real-time tracking tools like Lookout and Sentinel. But their resources are drying up. U.S. funding cuts and global vaccine scarcity are compounding risk. The world must act now: this outbreak is no longer localized, with G.1 cases already appearing in the U.S. and Europe. Sierra Leone cannot and should not face this epidemic alone.

Mpox Vaccine Shortfall - Jynneos (MVA-BN) Still Priced at a Premium

June 9, 2025

As Africa’s mpox outbreak escalates, vaccine supply remains dangerously inadequate. On June 5, 2025, Africa CDC’s Dr. Ngashi Ngongo flagged Bavarian Nordic’s high price for MVA-BN (Jynneos) as a key barrier. Despite 1.3 million doses allocated, over 6 million are still needed. UNICEF lacks funding to procure its remaining doses, and U.S.-pledged supplies face delays due to past administrative disruptions. With cases soaring in countries like Sierra Leone and DRC, continued supply scarcity—driven by unaffordable pricing—jeopardizes outbreak control. Bavarian Nordic must urgently lower MVA-BN’s price and enable technology transfer to ensure equitable access and protect global health.

Mpox epidemic remains international health emergency warns WHO

June 9, 2025

On June 5, 2025, WHO Director-General Dr. Tedros Adhanom Ghebreyesus reaffirmed mpox as a Public Health Emergency of International Concern, following the International Health Regulations Emergency Committee meeting. With over 37,000 confirmed cases and 125 deaths across 25 countries since early 2024, the epidemic remains deeply entrenched. The Democratic Republic of the Congo accounts for 60% of cases, while Uganda, Burundi, and Sierra Leone face mounting surges. Despite some progress, the resurgence in West Africa and undetected spread globally demand urgent international coordination, improved surveillance, and funding to prevent further escalation of this complex, transcontinental public health threat.

Analysis shows mpox lurked in Nigeria for 8 years before igniting global 2022 outbreak

June 6, 2025

A groundbreaking gene-tracking study published in Nature confirms that clade 2 mpox circulated in Nigeria undetected for eight years before triggering the 2022 global outbreak. Researchers estimate the virus first infected humans in southern Nigeria in 2014 and spread silently due to poor surveillance. Of 118 genomes analyzed, nearly all Nigerian cases showed sustained human-to-human transmission, while Cameroon cases reflected animal spillover. Lead author Edyth Parker stressed that limited access to vaccines, diagnostics, and surveillance tools in Africa facilitated the unchecked spread. The findings are a stark reminder: neglecting local epidemics endangers global health.

Sierra Leone battles intense mpox activity as Ethiopia reports first death

June 6, 2025

Mpox activity in Africa is escalating rapidly, with new surges in Sierra Leone and Ethiopia raising alarm. At a recent Africa CDC briefing, Dr. Ngashi Ngongo confirmed nearly 17,845 lab-confirmed cases by May—approaching 2024’s full-year total. Sierra Leone alone accounted for 53% of last week’s cases, and Ethiopia reported its first mpox-related death, an infant. Passive surveillance, high-density populations, and complex transmission dynamics are fueling the spread. Emergency declarations by Africa CDC and WHO remain under review. With new vaccine shipments arriving in the DRC, Sierra Leone, and Ethiopia, equitable distribution and intensified response remain critical for containment.

11 patients with confirmed, suspected mpox are HIV-positive

June 6, 2025

A recent cluster of mpox cases at the Southern Philippines Medical Center revealed a concerning overlap: 11 of 14 patients also tested positive for HIV. The majority were male, with no significant travel history, and transmissions likely occurred through close or sexual contact. While health authorities urge caution, they clarified that mpox is not airborne, and lockdowns are unnecessary. Facemask use is recommended in crowded spaces but not mandatory. With mpox declared a global public health emergency in 2024 and HIV infections in the Philippines surging, officials are calling for vigilance, testing, and community education on both diseases’ overlapping risks.

WHO Director-General's opening remarks at the IHR Emergency Committee meeting regarding the upsurge of mpox 2024 – 5 June 2025

June 5, 2025

In his opening remarks at the 5 June 2025 IHR Emergency Committee meeting, WHO Director-General Dr. Tedros Adhanom Ghebreyesus addressed the alarming mpox upsurge, citing over 37,000 confirmed cases and 125 deaths globally in 2024. The Democratic Republic of the Congo alone accounts for 60% of confirmed cases. Despite the deployment of 2.9 million vaccine doses across 13 countries, only 724,000 have been administered. Dr. Tedros called for urgent funding—$147 million—to sustain surveillance, response, and vaccination efforts. Amid rising transmission and widening geographic spread, he emphasized the critical need for cross-border coordination, local engagement, and sustained international commitment.

Mpox Research Is Helping Scientists Prepare for a New Pandemic

June 4, 2025

The 2022 global mpox outbreak, which struck the U.S. with over 20,000 cases, led to widespread use of tecovirimat (TPOXX) under emergency protocols. A major clinical trial led by UC San Francisco has now confirmed that while TPOXX was safe, it did not accelerate recovery. This mirrors findings from a parallel trial in the Democratic Republic of the Congo. The trial's inclusive design—incorporating pregnant women and children—underscores the ethical imperative of equitable research. As mpox remains a WHO-declared public health emergency, these findings emphasize the need for more robust antiviral strategies and continued investment in outbreak-responsive clinical trials.

Q&A: How mpox research is helping scientists prepare for a new pandemic

June 4, 2025

The mpox outbreak of 2022 devastated communities across the U.S., including San Francisco. Yet the widely used antiviral TPOXX failed to speed recovery in clinical trials led by UC San Francisco and the Democratic Republic of the Congo. While the drug was safe, results showed no significant benefit—underscoring the urgency of developing more effective therapeutics. The inclusion of pregnant women and children in open-label study arms marked an ethical advancement in clinical trial design. This experience demonstrates why real-time, equitable trials are essential during health emergencies to ensure that treatment strategies are both evidence-based and inclusive from the outset.

African countries fall far short of mpox vaccination targets

June 4, 2025

Africa’s escalating mpox crisis has been met with an underwhelming global vaccination response, jeopardizing containment efforts. Despite an initial goal to vaccinate 10 million people, only 720,000 have received vaccines across the continent, with supply shortfalls and logistical hurdles delaying rollout. In conflict-ridden hotspots like the Democratic Republic of the Congo, fragile health systems have buckled under rising cases. Africa CDC’s ring vaccination strategy has stalled, hindered by limited lab access and resource constraints. With global equity in question and manufacturers reluctant to share technology, African nations are left to stretch scant doses. Bold investments and regional production are urgently needed.

DOH 7 heightens alert for Mpox

June 3, 2025

The Department of Health Central Visayas Center for Health Development (DOH Central Visayas CHD) in the Philippines has issued a strong call for vigilance as mpox cases reemerge in the region. Highlighting the virus’s transmission through intimate contact and contaminated materials, authorities stress the importance of hygiene, respiratory etiquette, and early detection. Regional Director Joshua Brillantes urged compassion, accurate information, and community cooperation over fear and stigma. With enhanced surveillance now in place, residents are reminded to seek immediate medical care if symptoms appear and avoid misinformation. Public health remains a shared responsibility, and Central Visayas is prepared to respond with vigilance and transparency.

Spike in Mpox Cases

June 2, 2025

Liberia’s confirmation of 69 active mpox cases is a stark reminder that the region remains vulnerable to infectious disease threats. While the country has reported zero deaths, the circulation of both Clade IIa and IIb strains, coupled with regional mobility, poses a significant risk. The National Public Health Institute of Liberia (NPHIL) is acting swiftly, issuing a national health advisory and encouraging hygiene, surveillance, and institutional preparedness. As past outbreaks have shown, community engagement is critical. Continued vigilance, cross-border coordination, and public compliance are essential to prevent further spread and protect Liberia’s growing but still fragile health infrastructure.

Explosive mpox outbreak in Sierra Leone overwhelms health systems

June 2, 2025

Sierra Leone’s explosive mpox outbreak, now accounting for three-quarters of all new African cases, underscores an urgent need for expanded vaccine access and global attention. With limited bed capacity and only 61,000 vaccine doses received so far, the country is ill-equipped to manage a fast-spreading crisis. Scientists are puzzled by Clade IIb’s behavior, which mimics the more severe Clade Ib strain in transmission and symptoms. While sexual contact appears to be the primary driver, concerns linger about other transmission modes. Immediate vaccine deployment and international support are essential to avert regional spillover and prevent a broader global resurgence.

U.S. CDC issues alert as mpox outbreak in Central, East Africa leads to new cases in the U.S.

May 31, 2025

The CDC’s recent health alert underscores the seriousness of the Clade I mpox outbreak in Central Africa, particularly the Democratic Republic of the Congo. Although no sustained U.S. transmission has occurred, travel-linked cases signal a need for vigilance. Clade I is more severe than its Clade II counterpart and has caused fatalities abroad. Healthcare providers must be proactive—screening travelers, reporting suspected cases, and encouraging vaccination. The JYNNEOS vaccine remains protective against both clades. Now is not the time for complacency. Early detection and vaccination outreach are key to preventing a domestic resurgence of a more dangerous strain.

Twelve African Nations to Boost Cross-Border Efforts Against Mpox, Health Crises

May 31, 2025

The mpox outbreak in Africa underscores the urgent need for cross-border coordination. With over 16,000 confirmed cases and more than 1,180 deaths, 12 African nations have committed to a unified response framework. This agreement—facilitated by the World Bank, Africa CDC, WHO, and partners—will improve surveillance, streamline data sharing, and address transmission challenges across borders. Epidemics respect no borders; thus, regional cooperation is critical. By aligning resources and strengthening governance, Africa is taking a proactive stance in disease containment, resilience building, and equitable health access. It’s a blueprint for managing not only mpox but all future health emergencies.

Sierra Leone seeks help for growing mpox outbreak

May 31, 2025

Sierra Leone’s escalating mpox crisis—with over 3,300 cases and 16 deaths since January—underscores the urgent need for international support. Despite opening a 400-bed treatment center and vaccinating over 42,000 frontline workers, the country is struggling to keep pace. Deputy Health Minister Charles Senessie’s appeal for global assistance must be met with swift action. Mpox remains a public health emergency across Africa, and Sierra Leone’s containment efforts are vital not just locally, but regionally. Global solidarity, including vaccine donations and logistical support, is essential to prevent further spread and strengthen the nation’s strained health infrastructure.

Oregon health Q&A: What is the latest with mpox in Oregon?

May 31, 2025

As Oregon enters Pride season, it's encouraging that mpox cases remain low—just eight reported in 2025. Yet the virus has not disappeared. With intimate skin-to-skin contact remaining the primary mode of transmission, continued caution and vaccination are vital. Oregon Health Authority rightly urges those at risk to complete their two-dose vaccine series, which offers up to 80% protection. Summer festivities should not ignore public health. Ensuring access to mpox vaccines, especially for LGBTQ+ communities, is a proactive step toward safe celebration. Staying informed and vaccinated protects both individuals and the broader community.

Health authorities stress prevention as LGUs detect Mpox

May 29, 2025

The detection of mpox cases in South Cotabato and Iloilo has triggered swift action by local governments in the Philippines, reflecting a commendable emphasis on prevention. From mandatory masking among health personnel in Polomolok and Cagayan de Oro to enhanced isolation protocols in Iloilo, LGUs are proactively reinforcing public health measures. With rising community cases and no history of travel among patients, vigilance must remain high. Public compliance—especially through masking, hand hygiene, and early symptom reporting—is crucial. As we learned from COVID-19, early intervention and widespread community engagement are key to curbing outbreaks before they escalate.

Africa CDC Appeals for More Mpox Vaccines, as Ethiopia Reports first cases

May 29, 2025

Africa urgently needs 6.4 million mpox vaccines to contain a rapidly escalating outbreak centered in Sierra Leone, which now accounts for three-quarters of the continent's confirmed cases. With just 10,000 doses available in-country and cases reported in 19 nations—including Ethiopia’s first three—there is a critical shortfall. Africa CDC has appealed for global solidarity as new cases rise sharply, nearly matching 2024's total in just five months. Japan’s pledged 1.5 million LC16 vaccines are expected imminently, but sustained funding and strategic allocation are essential to prevent further regional spread and blunt the compounded impact of concurrent disease outbreaks.

Should Mpox Vaccination Be Offered to More Children and Adolescents

May 29, 2025

As mpox persists globally, new research published in The Lancet Infectious Diseases reinforces the JYNNEOS vaccine’s efficacy in mitigating disease severity, particularly in preventing the progression to disseminated lesions. With over 720,000 doses administered across seven African nations, and updated U.S. CDC vaccination guidelines targeting high-risk groups, coordinated efforts are critical. Yet, disparities persist: vaccine protection is significantly lower among HIV-positive individuals with weakened immunity. With mpox posing rising risks to children via household transmission, expanding vaccine access, especially in Africa where clade Ib is surging, is imperative to halt further spread and reduce global health inequities.

Ethiopia confirms first mpox cases

May 29, 2025

Ethiopia has confirmed its first mpox cases—a newborn and the infant’s parents—raising the number of African countries battling outbreaks to 25. The infections in Moyale, near the Kenyan border, likely involve clade 1b. Meanwhile, Sierra Leone continues to drive regional transmission, accounting for 74% of new confirmed cases. The Africa CDC warns that 6.4 million vaccine doses are urgently needed, yet nearly 570,000 pledged doses from the U.S. and UNICEF remain delayed due to funding uncertainties. As outbreaks expand, swift vaccine deployment, contact tracing, and field workforce mobilization remain critical to preventing further spread and averting a broader health emergency.

Florida disease-tracking chart returns: Measles, mpox, hepatitis surveillance now available

May 27, 2025

The restoration of Florida’s public disease surveillance data is a timely and crucial development. With rising mpox, measles, and pertussis cases, real-time information empowers clinicians, parents, and communities to respond swiftly and make informed decisions about vaccination and public health measures. Broward County, now leading in mpox cases, exemplifies why such transparency is essential. As vaccine-preventable diseases surge—amid dropping immunization rates—surveillance is not a luxury; it is a public health necessity. Florida’s decision to resume reporting is not just good governance—it is a safeguard for children and communities.

Malawi battles mpox as cases of the infectious disease surge in Africa

May 26, 2025

The confirmation of three new mpox cases in Lilongwe, Malawi, underscores the growing public health challenges the country faces amid donor aid cuts. With just 11 cases reported so far, Malawi joins 15 other African nations grappling with mpox while also contending with vaccine shortages, low public awareness, and strained testing capacity. The situation is further exacerbated by recent U.S. funding suspensions, which have decimated HIV programs and weakened broader healthcare infrastructure. Urgent investments in surveillance, public education, and cross-sector preparedness are essential to prevent mpox from escalating into yet another neglected health crisis.

12 African Countries Commit to Strengthen Cross-Border Collaboration for Improved Mpox and Health Emergency Response

May 23, 2025

Twelve African nations have signed a groundbreaking agreement to enhance cross-border collaboration against mpox and other infectious diseases, reinforcing the principle that epidemics recognize no borders. With over 16,000 confirmed mpox cases and 1,180 deaths across 22 countries, the new coalition—backed by Africa CDC, WHO, the World Bank, and other partners—seeks to streamline data-sharing, boost surveillance, and coordinate movement of affected populations. By uniting political will with technical support, the agreement aims to establish sustainable, regional responses to recurring outbreaks and marks a crucial step forward in achieving health security across East, Central, and Southern Africa.

Togo reports mpox outbreak as activity escalates in West Africa

May 23, 2025

Togo’s confirmation of three mpox cases marks the 25th African nation affected in the current outbreak, underscoring the virus’s relentless advance across West Africa. With Clade 2 identified and no clear source of infection, the detection raises concerns of silent community transmission. Meanwhile, Sierra Leone has become the epicenter, accounting for 61% of Africa’s cases last week. Health systems are overwhelmed, and genetic sequencing reveals a proliferation of Clade 2b sublineages. The rapid geographic spread and shifting transmission patterns highlight the urgent need for enhanced surveillance, diagnostic support, and vaccination to contain this escalating public health emergency.

Liberia: Health Authorities Request Additional Funding to Combat Mpox Outbreak

May 22, 2025

With four active mpox cases confirmed in Liberia, national health authorities have urged the House of Representatives for increased funding to contain the outbreak. Declared a global emergency by WHO, mpox requires swift and sustained action. Liberia’s Ministry of Health and NPHIL seek support for surveillance, diagnostics, and public awareness. However, lawmakers have raised serious concerns about transparency, demanding accountability for past funds, including US$700,000 allocated in the national budget. The call for urgent financial backing is clear, but so is the need for clarity on fund management to ensure an effective and trustworthy public health response.

New Mpox cases detected in Onondaga County

May 22, 2025

The recent detection of multiple mpox cases in Onondaga County underscores the importance of continued vigilance and public health readiness. Although all patients are recovering at home, officials are conducting contact tracing to prevent further spread. Mpox, primarily transmitted through close skin-to-skin or sexual contact, disproportionately affects gay and bisexual men. With only a handful of cases reported statewide this year, the risk remains low, but not negligible. The availability of effective vaccines and simple preventive practices—such as safer sex and good hygiene—remain critical tools. Public education and equitable vaccine access must remain priorities to prevent a broader resurgence.

Sierra Leone Fights Mpox

May 18, 2025

Sierra Leone’s mpox outbreak has reached alarming levels, accounting for half of Africa’s confirmed cases in early May. With only 60 isolation beds and over 1,000 active patients, the country is relying heavily on home-based care, where compliance is low. Despite good testing rates, weak contact tracing and passive surveillance are hampering control efforts. Though nearly 24,000 people have been vaccinated, vaccine supply is still inadequate. The crisis highlights the urgent need for expanded vaccine access, improved surveillance, and stronger international support. Africa CDC warns that without immediate action, the outbreak risks spreading further across West Africa.

Africa Turns to Mpox Lessons to Fight Cholera

May 18, 2025

The escalating cholera crisis in Africa, affecting over 178,000 people across 16 countries, underscores the urgent need for a coordinated, cross-border response. Africa CDC is considering adapting the successful mpox response model—based on multisectoral collaboration, unified strategy, and regional capacity-building—to tackle this waterborne threat. With conflict, weak surveillance, and insufficient vaccine supply exacerbating outbreaks, the proposed approach integrates cholera with existing frameworks, such as the Incident Management Support Team (IMST). Leveraging lessons from mpox offers a path forward, but sustained investment in sanitation, water infrastructure, and local vaccine manufacturing remains essential for long-term cholera control.

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa

May 16, 2025

The continued lack of an effective antiviral treatment for mpox, especially the severe Clade 1a and 1b strains, highlights a critical unmet medical need in global public health. With case fatality rates as high as 3–4%—and children disproportionately affected—current responses rely solely on vaccines and supportive care. NanoViricides' Phase II trial of NV-387 in the Democratic Republic of Congo marks a significant step forward. If successful, NV-387 could become the first targeted oral antiviral for mpox, fulfilling a long-standing treatment gap and reinforcing global health security amid a persistent public health emergency.

Mpox activity escalates in Sierra Leone

May 15, 2025

The alarming rise of mpox cases in Sierra Leone—611 last week alone—demands urgent international attention. Representing over half of all cases in Africa, the outbreak’s rapid spread, particularly in Freetown and its surrounding districts, signals a critical risk of cross-border transmission. While testing coverage remains robust, weak contact tracing hampers containment. Africa CDC’s vaccination campaign has already reached over 30,000 people in two weeks, but with 6.4 million doses needed continent-wide, urgent global support is essential. Mpox remains a public health emergency, and sustained investment in vaccines, contact tracing, and community education will be key to halting its escalation.

Sierra Leone's mpox cases fuel African outbreak, health body says

May 8, 2025

Sierra Leone now accounts for over half of Africa’s confirmed mpox cases this week, with 384 new infections—marking a 63% surge and underscoring the country’s central role in driving the continent’s outbreak, according to the Africa CDC. Limited funding, insufficient contact tracing, and inadequate treatment capacity—only 60 beds for 800 active cases—are compounding the crisis. Although cases are declining in Uganda and Burundi and stabilizing in the DRC, Sierra Leone's escalation highlights the urgent need for strengthened surveillance and resources. With WHO maintaining mpox’s classification as a public health emergency, the international community must prioritize response funding.

Sierra Leone battles mpox surge

May 8, 2025

Mpox cases in Sierra Leone are surging dramatically, with the country now averaging 100 new infections daily and accounting for half of Africa’s confirmed cases last week. The outbreak, driven by clade 2b, predominantly affects males aged 30 to 35 and includes a significant number of patients with HIV. While nearly 24,000 people—mainly health workers—have been vaccinated, limited isolation beds and low contact-tracing capacity hinder containment. Despite this, Africa CDC reports promising progress in other high-burden countries like Uganda, Burundi, and the DRC. Continued vigilance, funding, and expanded vaccination remain vital to halt the virus’s spread across the region.

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

May 6, 2025

Bavarian Nordic has secured a $143.6 million expansion of its contract with the U.S. government to supply freeze-dried JYNNEOS® smallpox/mpox vaccines, following FDA approval of the formulation in March 2025. The Biomedical Advanced Research and Development Authority (BARDA) exercised options to convert existing vaccine stock and support long-term shelf life, with deliveries expected in 2026. The freeze-dried version offers logistical advantages for national stockpiles. Since 2003, Bavarian Nordic has partnered with the U.S. on vaccine preparedness, and this latest investment underscores continued federal commitment to bolstering biosecurity and ensuring future mpox and smallpox response capacity.

Gavi delivers largest shipment yet to DRC in support of international mpox response

May 1, 2025

This week, the Democratic Republic of the Congo will receive 200,000 new mpox vaccine doses from Gavi, the Vaccine Alliance, bolstering the country’s response to one of the world’s most severe mpox outbreaks. With over 20,000 cases and 49 deaths reported by mid-April 2025, DRC has now received more than 950,000 doses in total. The new shipment will target high-risk regions, especially areas affected by mass displacement. This delivery, part of Gavi’s broader emergency response effort alongside WHO, Africa CDC, and UNICEF, underscores the critical importance of international solidarity in combatting Clade Ib mpox and preserving global public health.

United States (U.S.) Government Commits nearly $1 Million to Strengthen Mpox Response in Tanzania

April 29, 2025

The U.S. Centers for Disease Control and Prevention (CDC) has committed nearly $1 million to help Tanzania combat the spread of mpox. The funding will enhance infection surveillance, prevention, and control across both mainland Tanzania and Zanzibar. Resources will support health facilities, emergency operations centers, and public awareness campaigns, as well as bolster laboratory capacity and border screening. This collaboration reflects the U.S. government’s strategic investment in global health security, reinforcing Tanzania’s response capacity and safeguarding communities. Such partnerships are critical not only for local disease containment but also for preventing wider international transmission of emerging infectious threats like mpox.

Stockpiling for mpox emergencies

April 28, 2025

Recent mpox outbreaks have underscored the need for a sustainable global response. Gavi, the Vaccine Alliance, currently supports vaccine deployment in African countries and is planning to establish an emergency mpox vaccine stockpile. This initiative would ensure rapid response to future outbreaks and incentivize manufacturers to maintain production despite unpredictable demand. However, the creation of the stockpile depends on Gavi’s success in raising $9 billion for its 2026–2030 strategic cycle. A stockpile would move global health efforts beyond the current reliance on emergency donations and fragmented supplies, ensuring equitable and timely access to vaccines during future public health emergencies.

Mobile teams step up efforts to stop mpox

April 27, 2025

In North Kivu, Democratic Republic of the Congo, mpox cases are surging amid mass displacement caused by armed conflict. Over 3,300 suspected cases have been recorded this year. In response, UNICEF and partners have deployed 12 mobile vaccination teams to hard-hit areas like Goma. At Kabingo Primary School, children exposed to a confirmed case are receiving the vaccine to curb the spread. Community engagement is central to the campaign’s success, with students and parents advocating for vaccination after firsthand experiences with the disease. The initiative is supported by Gavi, the Mastercard Foundation, the UK FCDO, and the European Union.

Africa CDC to Review Mpox Emergency Status Amid Mixed Infection Trends

April 25, 2025

Africa CDC's Emergency Consultative Group will meet on 17 May 2025 to decide whether mpox should remain a public health emergency of continental concern. The review comes amid mixed epidemiological trends—while infections are falling in some countries like Burundi and Rwanda, others such as Uganda and Nigeria are seeing surges. Central Africa remains the epicentre, complicated by conflict, a drop in testing, and the emergence of a new Clade 1A variant. Meanwhile, vaccine rollout is expanding. The decision will influence future strategy, funding, and partnerships, with the updated response plan aiming to reduce incidence by 50% by August 2025.

African countries see payoff from ramped-up mpox strategies

April 25, 2025

Mpox cases in Africa have declined over the past six weeks, driven by intensified public health efforts like expanded community health worker contact tracing, according to Africa CDC officials. While Burundi and the DRC are showing promising declines, 17 of 24 affected countries still report active transmission. Malawi has newly confirmed community transmission of clade 1b mpox. Vaccination campaigns are scaling up, and rapid diagnostic tests are under evaluation to improve early case detection. Despite positive trends, officials remain cautious, citing conflicts, low testing rates, and concurrent outbreaks like measles as ongoing challenges to fully containing the virus.

Mpox Found in North Carolina Sewage: What to Know

April 24, 2025

North Carolina health officials are urging vigilance after clade I mpox virus was detected in wastewater samples from Greenville, signaling possible undiagnosed or unreported infections. The findings, uncovered through the state’s wastewater monitoring network, mark the first environmental detection of this more virulent mpox strain in the state. Although no confirmed clade I cases have been reported in North Carolina to date, officials stress the importance of monitoring symptoms and considering vaccination among high-risk groups. This alert underscores wastewater surveillance as an essential tool for early detection and community-level awareness in preventing potential mpox transmission.

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

April 24, 2025

Tonix Pharmaceuticals has unveiled promising preclinical data for TNX-801, a novel single-dose live-virus mpox vaccine, at the 2025 World Vaccine Congress. TNX-801, based on synthesized horsepox, showed strong protection against both rabbitpox and clade IIa mpox in animals—including immunocompromised models—after just one dose. The vaccine prevented clinical disease and lesion formation, supporting its potential as a safe, effective alternative to multi-dose vaccines. With mpox outbreaks involving clade IIb and clade Ib declared international emergencies by the World Health Organization, TNX-801’s alignment with WHO’s preferred vaccine profile strengthens its promise in bolstering global preparedness and rapid response to future epidemics.

Sierra Leone health workers line up for mpox jab amid growing outbreak

April 23, 2025

Sierra Leone has launched its first mpox vaccination campaign, prioritizing frontline health workers, close contacts of infected individuals, and security personnel. The drive follows a surge in cases since January, with 477 infections and three deaths. The 61,300 doses—58,300 from Gavi and the rest from Ireland—are being administered in hotspots, including at Freetown’s 34 Military Hospital. With community transmission now widespread, health officials are coupling immunization with public awareness campaigns to break the chain of infection. The campaign, backed by Africa CDC, WHO, and UNICEF, marks a crucial step in strengthening Sierra Leone’s outbreak response and protecting its most vulnerable.

Mpox detected in NC wastewater, health officials issue alert

April 22, 2025

North Carolina health officials are urging vigilance following the detection of Clade I mpox virus in wastewater samples from Greenville—the first such detection in the state. While no confirmed cases have been reported, the North Carolina Department of Health and Human Services warns that this could signal undiagnosed infections. Wastewater surveillance is an early-warning tool, and Clade I is a more severe strain linked to outbreaks in Central and Eastern Africa. Although public risk remains low, providers are advised to monitor symptoms and assess travel history. Funding for wastewater monitoring remains uncertain, posing a challenge for ongoing viral detection efforts.

Squirrels, Not Monkeys, May Be the Animal Source of Mpox, Researchers Suggest

April 18, 2025

A groundbreaking study in Ivory Coast has linked a deadly mpox outbreak among sooty mangabey monkeys to the fire-footed rope squirrel, providing the strongest evidence yet of this species' role in viral spillover. Researchers from the Helmholtz Institute traced the transmission from a squirrel consumed by a mother monkey to her offspring and then throughout the troop. This is the first confirmed cross-species transmission of mpox from a squirrel to primates in a wild setting. While further research is needed to determine if the rope squirrel is a reservoir host, the findings mark a critical step in understanding zoonotic mpox emergence.

Hospital contacts patients and staff over mpox case

April 17, 2025

Addenbrooke’s Hospital in Cambridge is investigating possible mpox exposure after a confirmed patient visited its emergency department. The hospital has contacted 30 patients and 20 staff who may have been in close proximity to assess risk and determine whether vaccines or symptom monitoring are necessary. The patient is now isolating at home. Though mpox, formerly known as monkeypox, was recently downgraded from a high-consequence infectious disease classification, it remains a public health concern due to its potential for close-contact transmission. UK Health Security Agency has been informed, and authorities stress that the public’s risk remains low.

Africa CDC and WHO update mpox strategy as outbreaks persist

April 17, 2025

Africa CDC and WHO have jointly updated their Continental Mpox Response Plan to reflect the growing urgency of the outbreak. With more than one million vaccine doses delivered and 650,000 administered—90% in the DRC—the revised plan focuses on controlling the outbreak while transitioning toward long-term resilience. Diagnostic capacity in the DRC has improved with 23 operational labs, but escalating conflict and aid cuts are hampering response efforts. Local transmission has now been reported in 11 African countries. The updated plan emphasizes sustained vaccination, diagnostics, and integration of mpox into routine health services to safeguard future public health.

Mpox is on the rise in Berlin with gay men seen most at risk

April 17, 2025

A sharp rise in mpox cases in Berlin has prompted health officials and LGBTQ+ advocates to call for an urgent vaccination campaign targeting gay and bisexual men. Berlin reported 43 cases in the first three months of 2025—quadruple the number during the same period in previous years. Unlike recent European cases tied to travel, most of Berlin’s cases are locally acquired, highlighting vaccine coverage gaps. While the infections are from Clade II and not the deadlier Clade Ib variant, public health experts emphasize that uninsured and newly arrived individuals must be reached through community-led, stigma-free health outreach and access.

Mpox drug Tpoxx didn't speed lesion healing in clade 1 patients, trial shows

April 17, 2025

A landmark clinical trial in the Democratic Republic of the Congo found that tecovirimat (Tpoxx), widely distributed for mpox treatment, was ineffective in accelerating healing or reducing pain for patients infected with clade 1 mpox. Published in the New England Journal of Medicine, the PALM007 study revealed no statistically significant differences in recovery time or mortality between patients treated with Tpoxx and those given a placebo. Researchers are now calling for the urgent development of alternative therapies, including combination antivirals and monoclonal antibodies, especially as severe outcomes remain high in under-resourced regions battling clade 1 mpox.

The world could stop central Africa’s deadly mpox outbreak if it wanted to

April 16, 2025

As global attention to mpox wanes, the virus continues to surge across Central Africa, particularly in the Democratic Republic of the Congo (DRC), where the more lethal clade I variant has caused over 16,000 cases and 500 deaths in 2024. Despite its severity, clade I has received little global investment in vaccines, diagnostics, or surveillance compared to clade IIb, which triggered global alarm in 2022. Scientists now warn of clade Ib, a new subvariant with increased transmissibility. Equitable vaccine access, rapid testing, and global coordination remain vital to stop the spread—before the outbreak jumps borders and becomes another preventable global crisis.

As Kenya awaits mpox vaccine roll-out, health workers drive rising public awareness of the virus

April 16, 2025

Kenya’s mpox outbreak, now confirmed in 13 counties, highlights the need for targeted public health interventions. Cases cluster along the Mombasa-Kampala transport corridor, disproportionately affecting sex workers and long-distance truck drivers. In Kiboko, a town on this route, local health workers identified mpox in a sex worker living with HIV, who later transmitted it to her children. Community-based surveillance, posters, and Red Cross support have helped stem transmission. On April 9, Kenya received 10,700 vaccine doses from Gavi. The rollout will prioritize vulnerable populations, but sustained community engagement and health education remain vital to curb this growing public health threat.

Mpox activity escalates in Uganda as vaccine shipments to Africa pass 1 million doses

April 11, 2025

Mpox continues to surge across Africa, with Uganda now accounting for half of all new cases, according to the Africa CDC. The continent is recording about 3,000 new cases weekly, driven largely by sexual transmission in densely populated urban areas. Uganda alone is grappling with concurrent outbreaks of mpox, Ebola, and Crimean-Congo hemorrhagic fever. While over 1 million vaccine doses have arrived across Africa, officials estimate 6.4 million are needed within six months to curb spread. Encouragingly, Uganda vaccinated 20,000 people in just one week. Testing challenges persist in conflict zones like eastern DRC, complicating surveillance and response efforts.

Vancouver Coastal Health urges mpox vaccinations amid recent increase in cases

April 9, 2025

Vancouver Coastal Health is urging men who have sex with men to ensure they are fully vaccinated against mpox, following a rise in cases. Nineteen infections have been reported in the region in 2025, most involving individuals who were unvaccinated or had only one vaccine dose. Officials emphasize that mpox, a virus related to smallpox, continues to circulate and spreads primarily through close personal contact. Less than half of eligible individuals have received both doses of the vaccine. With symptoms ranging from fever to painful rashes, health advocates stress the importance of awareness, community dialogue, and completing the two-dose series.

Switzerland confirms clade 1b mpox as Hong Kong issues warning

April 9, 2025

Switzerland has reported its first case of clade 1b mpox in a traveler returning from Africa, marking another addition to the list of countries detecting this more virulent strain. The patient is in isolation, and Swiss health officials confirm there is no risk of further transmission. Clade 1b is driving the current outbreak in central Africa, particularly in the Democratic Republic of the Congo. Meanwhile, the UK recently reported a clade 1b case with no travel history, prompting Hong Kong officials to issue public advisories. Clade 1b has now been detected in at least 15 countries across three continents.

How do mpox outbreaks start? Dead baby monkey provides important clue

April 8, 2025

A new preprint study has identified the fire-footed rope squirrel as a likely reservoir for mpox after an outbreak among mangabeys in Ivory Coast’s Taï National Park. Researchers traced the virus to a dead squirrel found months before the primate cases, suggesting cross-species transmission likely triggered the outbreak. The virus, previously believed to circulate primarily among rodents, may persist in rope squirrel populations. This breakthrough advances understanding of mpox’s zoonotic origins and raises questions about human-wildlife interactions in endemic areas. Scientists say this could help prevent future outbreaks by targeting surveillance and intervention where animal-to-human spillover risk is highest.

New Test Added to Recommended List of Molecular Diagnostic Tests for Mpox

April 7, 2025

Africa CDC has added the RADIONE Mpox Detection Kit to its list of recommended molecular diagnostic tests, marking a key advancement in expanding point-of-care (POC) diagnostics across the continent. Manufactured in South Korea by KH Medical, the test detects mpox DNA from clades I and II using automated PCR technology. It previously received WHO Emergency Use Listing in 2024 and passed independent evaluation in the DRC. With limited lab capacity still hindering timely diagnosis, this new addition supports the continent's six-month response plan focused on decentralizing testing and improving outbreak control amid ongoing mpox transmission in 22 African countries.

New 'surprising' case of mpox variant clade lb detected in England

April 7, 2025

The UK Health Security Agency (UKHSA) has confirmed a new clade 1b mpox case in northeast England, notably with no travel history or known connection to previous cases. Diagnosed in March, the patient’s contacts have been traced, and no additional cases have emerged. While UKHSA maintains that the public risk remains low, the unexplained transmission raises concerns about possible undetected community spread. Investigations are ongoing to determine the source of infection. The case underscores the need for continuous mpox surveillance and diagnostic preparedness, particularly as the clade 1b variant has proven more transmissible in other countries.

The Power of the Mpox Jab: Saving Lives in Kinshasa

April 7, 2025

In a groundbreaking move, the Democratic Republic of the Congo (DRC) became the first country to approve the MVA-BN (Jynneos) vaccine for children, launching a mass vaccination campaign in Pakadjuma targeting those aged 1 to 17. With support from Africa CDC, WHO, Gavi, and UNICEF, over 525,000 people were vaccinated—nearly 40% of them children. The campaign comes amid alarming statistics: children accounted for more than half of mpox cases and deaths in 2024. The DRC’s success, marked by high coverage and community trust, is a hopeful model for other nations now urged to approve pediatric use of MVA-BN.

Mpox case confirmed with no travel links

April 7, 2025

A Clade 1b mpox case has been confirmed in northeast England, with no known links to travel or existing cases, raising concerns about potential undetected community transmission. The UK Health Security Agency (UKHSA) is investigating the source of the infection, while maintaining that the overall public risk remains low. Though the disease was recently downgraded from its high-consequence infectious disease status, officials stress that mpox can still cause serious illness in some individuals. UKHSA urges the public to remain vigilant for symptoms such as rashes or fever and to seek medical advice if exposure or infection is suspected.

Mpox activity in Africa on pace to pass 2024 total

April 3, 2025

Mpox activity in Africa is escalating sharply, with nearly 50% of 2024’s total cases already reported in the first quarter of 2025, according to Africa CDC Director Dr. Jean Kaseya. Uganda, Burundi, and the Democratic Republic of the Congo (DRC) accounted for 95% of confirmed cases last week. In the DRC, only 18.4% test coverage further clouds the outbreak picture amid ongoing conflict and foreign aid cuts. Ghana also reported its first case in 11 weeks, prompting renewed surveillance efforts. Meanwhile, Africa CDC has launched a health financing strategy focused on boosting domestic investment, innovative levies, and regional vaccine production.

US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine

March 31, 2025

The U.S. FDA has approved a freeze-dried version of Bavarian Nordic’s Jynneos vaccine for mpox and smallpox, a key development for long-term emergency preparedness. Unlike the liquid-frozen formulation approved in 2019, the freeze-dried version offers improved shelf life and easier storage and transportation, ideal for global stockpiling. Developed under a U.S. BARDA contract, deliveries will begin in late 2025. This milestone comes as WHO continues to classify mpox as a public health emergency, with over 25,000 confirmed cases globally in 2024, including four U.S. cases of the more transmissible clade Ib. Broader vaccine access and storage stability are now critical.

UK no longer deems clade 1 mpox 'high consequence'

March 19, 2025

The UK Health Security Agency (HSA) has downgraded clade 1a and 1b mpox, determining they no longer meet the criteria for a high-consequence infectious disease due to their low mortality rates and the availability of vaccines and treatments. However, the agency stresses that mpox remains a public health threat, particularly for travelers to affected regions. Meanwhile, a U.S. National Institutes of Health (NIH) trial confirmed that tecovirimat (Tpoxx), once considered a promising treatment for mpox, is ineffective for clade 2 infections. These findings underscore the need for continued research into effective treatments and global surveillance of mpox outbreaks.

Estimates: Jynneos mpox vaccine 84% and 35% effective in people without, with HIV

March 19, 2025

A recent study published in The Lancet Infectious Diseases found that a single dose of the Jynneos vaccine is 58% effective against mpox overall but significantly less effective (35%) in people with HIV compared to 84% in those without. Conducted across multiple countries, the study also highlighted reduced symptom severity and faster recovery in vaccinated individuals. Researchers stress the importance of completing a two-dose regimen, particularly for immunocompromised individuals. Experts call for expanded research in Central Africa, where clade 1 mpox is endemic, emphasizing the need for stronger vaccination strategies to protect high-risk populations and prevent global outbreaks.